Biotechnology company Oxolife S.L. (Spain), the Energy Balance, Puberty and Reproductive Health research group of the University of Cordoba (Spain) and the Human Growth and Reproductive Development research group at Rutgers University have initiated a triple international collaboration to further investigate the direct mechanisms of the drug OXO-001, designed to improve embryo implantation and to treat infertility associated with Polycystic Ovary Syndrome (PCOS). Barcelona-based biotech Oxolife is developing OXO-001, a drug for reproductive medicine that enhances and improves the embryo implantation process through a direct effect on the endometrium and also improves ovulation. The treatment will provide a solution to an unmet medical need, as there is currently no drug on the market aimed at improving embryo implantation.  To read the full story.